본문 바로가기
KERD
논문KCI 등재

국소진행성 두경부암에서 선행항암화학요법제로 사용되는 Paclitaxel과 Cisplatin 병용요법의 비용-효과성

Cost-Effectiveness of Paclitaxel plus Cisplatin as a Neoadjuvant Chemotherapy for Locally Advanced Head and Neck Cancer

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

주제분류약학

초록

This study was conducted to analyze cost-effectiveness of neoadjuvant chemotherapy for locally advanced head and neck cancer in Korean healthcare setting. We constructed a decision analytical model to estimate total costs and outcomes of paclitaxel+cisplatin (PC) or docetaxel+cisplatin+5-FU (DCF) for 2 years time horizon in 100 patient cohort with locally advanced head and neck cancer. Base analysis showed that cost savings of PC regimen were 379 million Korean Won and 231 million Korean Won in societal and payer's perspectives, respectively, compared to DCF regimen,and life saved was 0.18. PC regimen as a dominant strategy was found to be robust through sensitivity analyses.

Abstract

This study was conducted to analyze cost-effectiveness of neoadjuvant chemotherapy for locally advanced head and neck cancer in Korean healthcare setting. We constructed a decision analytical model to estimate total costs and outcomes of paclitaxel+cisplatin (PC) or docetaxel+cisplatin+5-FU (DCF) for 2 years time horizon in 100 patient cohort with locally advanced head and neck cancer. Base analysis showed that cost savings of PC regimen were 379 million Korean Won and 231 million Korean Won in societal and payer's perspectives, respectively, compared to DCF regimen,and life saved was 0.18. PC regimen as a dominant strategy was found to be robust through sensitivity analyses.

참고문헌 (25)

  1. "Korea Cancer Statistics 2000"[URL]
  2. Licitra L, "Is there still a role for neoadjuvant chemotherapy in head and neck cancer?", Annals of Oncology, 15, pp.7~11 (2004)
  3. Specenier PM, "Neoadjuvant chemotherapy in head and neck cancer: Should it be revised?", Cancer Letters, 256, pp.166~177 (2007)
  4. 성인고형암치료임상연구센터, "두경부암 치료권고안", ~ (2005)
  5. Adelstein DJ, "Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer", J Clin Onco, 24, pp.2624~2628 (2006)
  6. Schrijvers D, "Taxanes in the treatment of head and neck cancer", Current Opinion in Oncology, 17, pp.218~224 (2005)
  7. Lang K, "The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data", Arch Otolaryngol Head Neck Surg, 130, pp.1269~1275 (2004)
  8. Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
  9. Vermorken JB, "Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer", N Engl J Med, 357, pp.1695~1704 (2007)
  10. "의약품정보"[URL]
  11. A Phase 2 Trial of Neoadjuvant Paclitaxel and Cisplatin in Patients with Locally Advanced Head and Neck Cancer, "Bristol-Myers Squibb Company", ~, pp.Final Clinical Study Report for Study CA139384 (2007)
  12. Kim H, "Induction Chemotherapy using 5-FU and Cisplatin and Radiotherapy in Patients with Locally Advanced Head and Neck Cancer", 대한내과학회지, 49(4), pp.484~491 (1995)
  13. Cho EK, "Combination Chemotherapy with 5-Fluorouracil and Carboplatin for Advanced Head and Neck Cancer", Joural of Korean Cancer Association, 28(1), pp.95~103 (1996)
  14. Dunphy FR, "Induction paclitaxel and carboplatin for patients with head and neck carcinoma", Cancer, 91, pp.940~948 (2001)
  15. Cho E, "Docetaxel and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Cancer", 대한두경부종양학회지, 21(2), pp.126~131 (2005)
  16. Rapidis AD, "Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up", Oral oncology, 42, pp.675~684 (2006)
  17. Posner MR, "Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy", Oncologist, 10(Suppl3), pp.11~19 (2005)
  18. 건강보험심사평가원, "약제급여목록 및 상한금액표", ~ (2008)
  19. 건강보험심사평가원, "의약품 주성분별 가중평균가격 -2008년 하반기", ~ (2009)
  20. Mosteller RD, "Simplified calculation of body surface area", N Engl J Med, 317(17), pp.1098~ (1987)
  21. 대한의사협회, "건강보험요양급여비용 2008년 1월판", ~ (2008)
  22. 보건복지부한국보건사회연구원, "국민건강영양조사 제3기 (2005)", ~ (2006)
  23. 노동부, "임금구조 기본통계조사 보고서 2007년판", ~
  24. Patrick DL, "Health status and health policy : quality of life in health care evaluation and resource allocation" (1993), Oxford University Press

관련 논문AI추천

진행성 두경부암의 Docetaxel과 Cisplatin의 항암화학요법의 치료효과김용대, 배창훈, 송시연, 최성원, 최영호영남대학교 의과대학 · Journal of Yeungnam Medical Science2006 · 제23권 제2호두경부암의 항암화학요법여창기대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2014 · 제57권 제5호Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck김문진, 김성민, 김혜숙, 박근칠, 선종무, 안명주, 장원진, 정현애, 최문기, 홍정용대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제5호The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer김여경, 김형준, 양덕환, 이제중, 이준규, 임상철, 정웅기, 정익주, 조상희, Jae-Sook Ahn, Ok-Ki Kim대한암학회 · Cancer Research and Treatment2007 · 제39권 제3호두경부 편평세포암종에서 선행항암화학요법과연속적 화학방사선 동시요법태경, 강석영, 금효섭, 김인순, 안명주, 이명자, 이형석, 전하정, 최정혜대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2007 · 제50권 제4호항암제 경제성평가에서 점증적 비용-효과비와 의사결정강영주, 강혜영, 고수경, 김회상한국보건의료기술평가학회 · 보건의료기술평가2014 · 제2권 제1호

이 간행물의 다른 논문 (11건)